ArticleOncology letters2026
Leucovorin enhances curcumin-induced inhibition of cell viability and ferroptosis in colorectal cancer cells.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is one of the leading causes of cancer-related mortality. Curcumin can inhibit the viability and induce ferroptosis in CRC cells, while leucovorin is known to enhance the cytotoxic effects of fluorouracil in the same cells. Therefore, the present study aimed to investigate whether leucovorin could potentiate curcumin-induced inhibition of cell viability and induce ferroptosis in CRC cells. The CRC cell lines, Caco-2 and HCT116, were treated with 50 µM curcumin, 2 µM leucovorin, a combination of curcumin and leucovorin, or leucovorin pre-treatment followed by co-treatment with curcumin and leucovorin. Cell viability and ferroptosis were assessed after 24 h of treatment. The results indicated that curcumin suppressed the viability of both Caco-2 and HCT116 cells. Furthermore, it also reduced glutathione, mitochondrial membrane potential and the protein expression levels of solute carrier family 7 member 11, while increasing the levels of malondialdehyde, reactive oxygen species, ferrous iron and the expression levels of acyl-CoA synthetase long chain family member 4, thus indicating that curcumin could induce ferroptosis in these cells. Cell treatment with curcumin and leucovorin further suppressed cell viability compared with curcumin alone in both cell lines. Furthermore, this combination, compared with curcumin alone, more notably promoted ferroptosis in HCT116 cells compared with that in Caco-2 cells. However, pre-treatment with leucovorin followed by co-treatment with curcumin and leucovorin had no further effect on cell viability or ferroptosis compared with the synchronous treatment of Caco-2 and HCT116 cells with curcumin and leucovorin. In conclusion, leucovorin could potentiate curcumin-induced inhibition of CRC cell viability and ferroptosis. However, additional leucovorin pre-treatment did not display further benefits compared with curcumin and leucovorin co-treatment. The findings of the present study suggested that curcumin and leucovorin may serve as a potential regimen for the treatment of CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.